Your Health, We Care
ARROW research shows that pralsetinib has excellent anti-tumor activity and controllable safety in RET fusion positive NSCLC patients. The research results have been published in top international academic journals such as Lancet Oncol and Ann Oncol.
Pralsetinib has been unanimously recommended by authoritative guidelines such as NCCN and ESMO for the treatment of advanced NSCLC patients with RET fusion.
